Indeed many studies have observed that GLP-1 RA treatment is associated with favourable changes in risk factors or markers for cardiovascular disease such as blood pressure, triglycerides, low density lipoprotein cholesterol (LDL-C), C-reactive protein and adiponectin, as reviewed 29. This evidence concerns the gene GCG and cardiovascular disorder.